Estimated economic costs of overactive bladder in the United States

被引:191
|
作者
Hu, TW
Wagner, TH
Bentkover, JD
LeBlanc, K
Piancentini, A
Stewart, WF
Corey, R
Zhou, SZ
Hunt, TL
机构
[1] Univ Calif Berkeley, Sch Publ Hlth, Dept Hlth Econ, Berkeley, CA 94720 USA
[2] Stanford Univ, Stanford, CA 94305 USA
[3] Dept Vet Affairs, Stanford, CA USA
[4] Innovat Hlth Solut, Brookline, MA USA
[5] Innovat Med Res, Baltimore, MD USA
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Pharmacia Corp, Peapack, NJ USA
关键词
D O I
10.1016/S0090-4295(03)00009-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To estimate the economic costs of overactive bladder (OAB), including community and nursing home residents, and to compare the costs in male versus female and older versus younger populations. Methods. The National Overactive Bladder Evaluation Program included a representative telephone survey of 5204 community-dwelling adults 18 years and older in the United States and a follow-up postal survey of all individuals with OAB identified and age and sex-matched controls. The postal survey asked respondents about bladder symptoms, self-care use, treatment use, work loss, and OAB-related health consequences. Survey data estimates were combined with year 2000 average cost data to calculate the cost of OAB in the community. Institutional costs were estimated from the costs of urinary incontinence in nursing homes, limited to only those with urge incontinence or mixed incontinence (urge and stress). Results. The estimated total economic cost of OAB was $12.02 billion in 2000, with $9.17 and $2.85 billion incurred in the community and institutions, respectively. Community female and male OAB costs totaled $7.37 and $1.79 billion, respectively. The estimated total cost was sensitive to the estimated prevalence of OAB; therefore, we calculated the average cost per community-dwelling person with OAB, which was $267 per year. Conclusions. By quantifying the total economic costs of OAB, this study-the first obtained from national survey data-provides an important perspective of this condition in society. The conservative estimates of the total cost of OAB were comparable to those of osteoporosis and gynecologic and breast cancer. Although this provides information on the direct and indirect costs of OAB, quality-of-life issues must be taken into account to gain a better understanding of this condition. (C) 2003 Elsevier Inc.
引用
收藏
页码:1123 / 1128
页数:6
相关论文
共 50 条
  • [21] COST EFFECTIVENESS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES
    Chen, J., V
    Klein, T. M.
    Mudd, P.
    VALUE IN HEALTH, 2021, 24 : S235 - S235
  • [22] Diagnosing overactive bladder using the overactive bladder-validated 8 in a primary care population in the United States.
    Elinoff, V
    Zyczynski, T
    Bavendam, T
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 95 - 95
  • [23] COMPARISON OF HEALTHCARE COSTS AND RESOURCE UTILIZATION FOR OVERACTIVE BLADDER PATIENTS IN THE UNITED STATES PERSISTING WITH MIRABEGRON TREATMENT OR SWITCHING TO ONABOTULINUMTOXINA
    Ng, D. B.
    Espinosa, R.
    Johnson, S.
    Walker, D.
    Gooch, K.
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 : S362 - S363
  • [24] A review: Differing costs and effects in economic evaluations of tolterodine for the treatment of overactive bladder
    Snedecor, S. J.
    Botteman, M. F.
    Weinstein, D.
    Trocio, J.
    VALUE IN HEALTH, 2008, 11 (03) : A302 - A302
  • [25] Impact of overactive bladder on women in the United States: results of a national survey
    Dmochowski, Roger R.
    Newman, Diane K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (01) : 64 - 75
  • [26] BUDGET IMPACT ANALYSIS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES
    Nesheim, J.
    Chen, J., V
    Gahn, J. C.
    Mudd, P.
    VALUE IN HEALTH, 2021, 24 : S234 - S235
  • [27] Economic costs of hepatocellular carcinoma in the United States
    Gondek, K.
    Lang, K.
    Danchenko, N.
    Shah, S.
    Anderson, S.
    Thompson, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] The economic costs of heroin addiction in the United States
    Mark, TL
    Woody, GE
    Juday, T
    Kleber, HD
    DRUG AND ALCOHOL DEPENDENCE, 2001, 61 (02) : 195 - 206
  • [29] Economic costs of biological invasions in the United States
    Fantle-Lepczyk, Jean E.
    Haubrock, Phillip J.
    Kramer, Andrew M.
    Cuthbert, Ross N.
    Turbelin, Anna J.
    Crystal-Ornelas, Robert
    Diagne, Christophe
    Courchamp, Franck
    SCIENCE OF THE TOTAL ENVIRONMENT, 2022, 806
  • [30] Economic costs of wind erosion in the United States
    Irene Y. Feng
    Thomas E. Gill
    R. Scott Van Pelt
    Nicholas P. Webb
    Daniel Q. Tong
    Nature Sustainability, 2025, 8 (3) : 307 - 314